Cell-Free DNA Cancer Screening: Can a Blood Test Detect Cancer Before Symptoms Appear?

Consider the math on cancer mortality in the United States. Approximately 611,000 Americans die from cancer each year. The vast majority of those deaths come from cancers detected at Stage III or IV — when treatment options are limited and survival rates plummet.

The fundamental problem: we routinely screen for only 4–5 cancer types in the United States today. Breast, cervical, colorectal, and lung (for high-risk smokers). Everything else — pancreatic cancer, ovarian cancer, liver cancer, esophageal cancer, and more than 45 other types — gets found when a patient develops symptoms. Which is often Stage III or IV.

Approximately 70% of cancer deaths in the U.S. come from cancers that have no standard-of-care screening test. Cell-free DNA multi-cancer early detection (MCED) testing is the most promising technology I’ve seen in my career for changing this statistic. It’s not perfect — and I’ll be honest about the limitations — but the data from the largest clinical study in genomic medicine history is genuinely compelling.

What Is Cell-Free DNA Cancer Screening?

When cells die and break down — as they do constantly throughout your body — they release DNA fragments into the bloodstream. This is called cell-free DNA (cfDNA). Tumor cells, which divide rapidly and die frequently, contribute a disproportionate share of this circulating DNA.

Multi-cancer early detection tests analyze the cfDNA in a blood sample for epigenetic signatures — specifically, DNA methylation patterns — that are characteristic of cancer cells from different tissues. Different cancers have distinct methylation signatures, allowing the test not only to detect a cancer signal but to predict where in the body it’s originating.

The leading MCED platform currently available is GRAIL’s Galleri test, which uses targeted methylation sequencing of cfDNA to detect signals from more than 50 cancer types. The Episeek platform, which Pravida Health uses, employs similar cfDNA epigenomic technology optimized for multi-cancer detection through bisulfite conversion and PCR-based amplification.

Why It Matters: What the Research Actually Shows

The PATHFINDER 2 Trial — The Largest Cancer Screening Study in History

The PATHFINDER 2 trial is the largest U.S. interventional study of a multi-cancer early detection test ever conducted. Published October 2025 at the ESMO Congress, it enrolled 35,878 participants across the U.S. and Canada, all aged 50 or older with no signs or symptoms of cancer.

The key findings from the pre-specified analysis of 23,161 analyzable participants:

• 7-fold increase in cancer detection rate when Galleri was added to standard recommended screenings (breast, cervical, colorectal, lung)
• 53.5% of Galleri-detected cancers were Stage I or II — early, potentially curable stages
• 69.3% were detected at Stages I–III — before the disease had spread systemically
• 99.6% specificity — false positive rate of only 0.4%, meaning 99.6% of people without cancer get a correct “no signal” result
• 73.7% episode sensitivity for the 12 deadliest cancer types (responsible for two-thirds of U.S. cancer deaths)
• 92% accuracy in identifying the tissue of origin — guiding efficient, targeted diagnostic workup

The positive predictive value (PPV) — the probability that a positive test result actually means cancer — was 61.6%, substantially higher than in earlier versions of the study.

The NHS-Galleri Trial: Honest Assessment

The NHS-Galleri trial — a randomized controlled trial of 142,000 participants in England’s National Health Service, results reported February 2026 — provides additional data with important nuances.

What it showed:

• 4-fold higher overall cancer detection rate compared to standard of care screening alone
• Substantial reduction in Stage IV diagnoses for the 12 pre-specified deadly cancers
• Greater than 20% reduction in Stage IV diagnoses in the second and third screening rounds

The nuance: the primary endpoint — a statistically significant reduction in combined Stage III–IV cancer diagnoses — was not met in the initial reporting period. However, a favorable trend was observed, and Stage IV reductions grew stronger with each year of sequential screening. The cancer detection benefit appears real and clinically meaningful. Whether it translates to statistically significant mortality reduction in a 3-year trial is a higher bar — one that even established screening tests like mammography took decades of follow-up to definitively demonstrate.

Stage-Dependent Sensitivity: The Limitation You Should Know

The most important limitation of cfDNA cancer screening is sensitivity — particularly for early-stage cancers. Using CCGA (Circulating Cell-free Genome Atlas) study data:

• Stage I sensitivity: approximately 16.8%
• Stage II sensitivity: approximately 40.4%
• Stage III sensitivity: approximately 77.0%
• Stage IV sensitivity: approximately 90.1%

This means a Stage I cancer has roughly a 1 in 6 chance of being detected. That is not as impressive as the overall headlines suggest. However, this is still better than the alternative — which for most cancers is no early detection test at all. Stage I pancreatic cancer, ovarian cancer, and liver cancer are rarely caught by any current standard method. The sensitivity is also improving: the PATHFINDER 2 data showed 73.7% episode sensitivity for the 12 most lethal cancer types, a meaningful improvement over earlier iterations.

The Gap in Standard Care

Current cancer screening in the U.S. covers only a handful of cancer types and is heavily dependent on symptom-based presentation. The status quo means: for 70% of cancers that kill Americans, the detection strategy is “wait for you to feel sick and then check.”

MCED testing doesn’t fully solve this — the sensitivity limitations are real — but it meaningfully changes the odds. If a 55-year-old gets an annual Galleri test alongside standard screenings, and that test catches a pancreatic cancer at Stage II instead of Stage IV, the five-year survival rate goes from approximately 3% to approximately 33%. That’s a 10-fold improvement in survival probability from a single blood draw.

How We Use This at Pravida Health

Cell-free DNA cancer screening (Episeek) is included in our Executive Health membership tier, used as a complement to — not a replacement for — other cancer screening modalities. Our clinical integration is built around five principles:

1. Annual testing cadence. We run cfDNA screening annually, which is important because cancer is a dynamic process. The methylation signature of a growing tumor becomes more detectable over time. Annual screening provides multiple detection opportunities and aligns with the NHS-Galleri and PATHFINDER 2 protocols.
2. Paired with full-body MRI. For Executive Health members, cfDNA and WB-MRI provide complementary coverage — cfDNA detecting circulating tumor signals from biochemical markers, WB-MRI detecting anatomical masses. Different mechanisms, different strengths, broader combined coverage. Schedule a consultation to learn how these two technologies work together in our program.
3. Paired with genomic risk context. Knowing your BRCA, Lynch syndrome, and other cancer predisposition status from whole genome sequencing — available through our precision genomics program — informs how aggressively we pursue a positive cfDNA signal and which tissue of origin predictions warrant immediate versus watchful investigation.
4. Managed diagnostic follow-up. When a signal is detected, we coordinate the diagnostic workup. A median of 46 days to diagnostic resolution (as reported in PATHFINDER 2) is achievable only when there’s a clinical team managing the process from signal to resolution.
5. Transparency about limitations. I tell every patient clearly: a negative cfDNA result does not mean you don’t have cancer. It means no detectable signal in your blood on this day. You still need your colonoscopy, your mammogram, your PSA. This is an additive tool, not a substitute.

What You Can Do Today

1. If you’re over 50, consider MCED testing. The risk-benefit calculation for adults 50 and older with average or elevated cancer risk is compelling, particularly given the 0.4% false positive rate and the 7-fold increase in cancer detection demonstrated in PATHFINDER 2. Contact us to discuss whether cfDNA screening fits your health profile.
2. If you have a cancer family history, consider it earlier. Adults in their 40s with significant family history of cancer types without standard screening options — pancreatic, ovarian, liver, esophageal — are reasonable candidates for earlier MCED screening.
3. Don’t let MCED replace standard screenings. Galleri’s sensitivity for breast and colorectal cancer is lower than dedicated mammography and colonoscopy respectively. These tests remain essential. MCED is an addition to your screening protocol, not a substitution.
4. Understand what a positive result means. A positive MCED result is not a cancer diagnosis — it’s a signal warranting diagnostic workup. The positive predictive value in PATHFINDER 2 was 61.6%, meaning about 4 in 10 positive signals don’t lead to a confirmed cancer diagnosis. That’s worth knowing before you test, and why physician-guided interpretation is essential.
5. Ask about the Episeek platform at Pravida. The Episeek cfDNA technology uses bisulfite conversion and PCR-based methylation analysis with machine learning interpretation — providing multi-cancer detection with a focus on the cancers with the highest mortality impact. Speak with a Pravida physician about whether Executive Health membership with integrated cfDNA screening is right for you.

Frequently Asked Questions